Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
All content for Wired to be Weird is the property of Ian McLaughlin & Bo Allen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
Why are some so skeptical of the disease model of addiction, while institutions like NIDA and the NIH embrace it? Should the NIH adjust its perspective? And what is Ian's opinion?
Wired to be Weird
Bo and I discuss some of the leading candidates for extending both human lifespan and “health-span”, including metformin, nicotinamide riboside & nicotinamide mononucleotide, and caloric restriction. We also chat about some of the companies working in this area, as well as novel business models that may or may not be a strategy to enable rigorous research of something as difficult to study as human lifespan.
